All In Biotech

Drug Trial Radar · NCT02680041

18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment

The Impact of 18F Fluciclovine (FACBC) PET/CT (Positron Emission Computed Tomography) on Management of Patients With Rising PSA (Prostate-specific Antigen) After Initial Prostate Cancer Treatment

Last checked: Nov 20, 2026Latest source record: Jan 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

221

Actual

Start

Jun 1, 2016

Primary completion

Nov 1, 2017

Study completion Nov 1, 2017

Sponsor

Lead sponsor
Blue Earth DiagnosticsIndustry
Sponsor type
Industry
Collaborators
American College of Radiology; IND 2 Results LLC; Syne Qua Non Limited
First posted
Feb 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective study will enroll up to 330 men with PSA-persistent or PSA-recurrent prostate cancer after curative-intent primary therapy and negative or equivocal findings on standard-of-care imaging. Consenting participants will be imaged with 18F-fluciclovine PET/CT. Site clinicians will manage study subjects per standard practices and will document any change in treatment based on review of 18F-fluciclovine PET/CT findings. All participants will be followed for up to 6 months, with clinical data collected for this study. An interdisciplinary panel will provide expert guidance to local readers on request. The final reporting of the PET/CT scan will be a single report by the local reader following any such discussion.

Conditions

  • Prostate Cancer

Interventions

  • 18F-fluciclovine PET CTDrug

    Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Planned Treatment Through Detection of Disease.Time frame: 2-22 days post PET CT

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Tower Urology

    Los Angeles, California

  • Genesis Research, LLC

    San Diego, California

  • University of Florida

    Jacksonville, Florida

  • Loyola University Medical Center

    Maywood, Illinois

  • Roudebush VA Medical Center

    Indianapolis, Indiana

  • University of Louisville

    Louisville, Kentucky

  • Washington University School of Medicine

    St Louis, Missouri

  • Coastal Urology Associates

    Brick, New Jersey

  • Manhattan Medical Research

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Urologic Consultants of SE Pennsylvania

    Bala-Cynwyd, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • University of Utah, Huntsman Cancer Institute

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.